| Symbol | LXEO |
|---|---|
| Name | LEXEO THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 345 PARK AVENUE SOUTH,6TH FLOOR, NEW YORK, New York, 10010, United States |
| Telephone | 212-547-9879 |
| Fax | — |
| — | |
| Website | https://www.lexeotx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001907108 |
| Description | Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreichs ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York. Additional info from NASDAQ: |
Otero Jose Manuel 🔴 sold 1.3K shares of Lexeo Therapeutics, Inc. (LXEO) at $5.07 Transaction Date: May 18, 2026 | Filing ID: 000009
Read moreTownsend Richard Nolan 🔴 sold 3.3K shares of Lexeo Therapeutics, Inc. (LXEO) at $5.06 Transaction Date: May 18, 2026 | Filing ID: 000011
Read moreLexeo Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
Read more📋 Townsend Richard Nolan (Officer) plans to sell 3K shares of Lexeo Therapeutics, Inc. (at $5.06 each, total $17K) Filed: May 18, 2026 | ID: 003723
Read more📋 Adler Eric (Officer) plans to sell 2K shares of Lexeo Therapeutics, Inc. (at $5.06 each, total $8K) Filed: May 18, 2026 | ID: 003716
Read moreNew Form SCHEDULE 13G/A - Lexeo Therapeutics, Inc. <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0001104659-26-062613 <b>Size:</b> 12 KB
Read moreNew Form SCHEDULE 13G/A - Lexeo Therapeutics, Inc. <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0001193125-26-225157 <b>Size:</b> 142 KB
Read more(19% Negative) LEXEO THERAPEUTICS, INC. (LXEO) Reports Q2 2026 Financial Results
Read moreLexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights
Read moreSepp-Lorenzino Laura 🟢 acquired 50.0K shares (1 derivative) of Lexeo Therapeutics, Inc. (LXEO) at $5.81 Transaction Date: Apr 28, 2026 | Filing ID: 000003
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06865482 | Clinical Course Of Disease In Participants With FA-CM | — | Friedreich Ataxia | Recruiting | 2025-09-30 | 2027-09-01 | ClinicalTrials.gov |
| NCT07050160 | Long-term Follow-up Study of Gene Therapy for Arrhythmogenic Cardiomyopathy Due… | — | Arrhythmogenic Cardiomyopathy | Enrolling_By_Invitation | 2025-08-29 | 2030-08-01 | ClinicalTrials.gov |
| NCT06109181 | Gene Therapy for ACM Due to a PKP2 Pathogenic Variant | Phase1 | Arrhythmogenic Cardiomyopathy | Active_Not_Recruiting | 2024-02-29 | 2027-03-01 | ClinicalTrials.gov |
| NCT06976606 | A Study to Assess Real-world Patient Characteristics and Clinical Course for Sy… | — | Arrhythmogenic Cardiomyopathy | Recruiting | 2024-01-23 | 2027-09-01 | ClinicalTrials.gov |
| NCT05400330 | Long-Term Follow-up of Gene Therapy for APOE4 Homozygote Alzheimer's Disease | Phase1 | Alzheimer Disease | Active_Not_Recruiting | 2023-05-08 | 2028-11-01 | ClinicalTrials.gov |
| NCT05445323 | Gene Therapy for Cardiomyopathy Associated With Friedreich's Ataxia | Phase1 | Friedreich Ataxia | Active_Not_Recruiting | 2022-08-24 | 2029-09-01 | ClinicalTrials.gov |
| NCT03634007 | Gene Therapy for APOE4 Homozygote of Alzheimer's Disease | Phase1 | Alzheimer Disease | Completed | 2019-11-06 | 2024-11-07 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| LX1001 | Other | Phase PHASE1 | Alzheimer Disease | ACTIVE_NOT_RECRUITING | NCT05400330 |
| LX1001 | Other | Phase PHASE1 | Alzheimer Disease | COMPLETED | NCT03634007 |
| LX2020 | Other | Phase PHASE1 | Arrhythmogenic Cardiomyopathy | ACTIVE_NOT_RECRUITING | NCT06109181 |
| High Dose LX2006 | Other | Phase PHASE1 | Friedreich Ataxia | ACTIVE_NOT_RECRUITING | NCT05445323 |
| Mid Dose LX2006 | Other | Phase PHASE1 | Friedreich Ataxia | ACTIVE_NOT_RECRUITING | NCT05445323 |
| Low dose LX2006 | Other | Phase PHASE1 | Friedreich Ataxia | ACTIVE_NOT_RECRUITING | NCT05445323 |